Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $26.73, for a total transaction of $317,579.13. Following the transaction, the chief operating officer directly owned 377,802 shares in the company, valued at approximately $10,098,647.46. The trade was a 3.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.47, for a total transaction of $302,609.07.
- On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.45, for a total transaction of $338,014.45.
- On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.04, for a total transaction of $309,381.24.
- On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total transaction of $296,787.38.
- On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total transaction of $285,738.05.
- On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
- On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total value of $304,272.41.
- On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total value of $302,965.50.
- On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total value of $304,866.46.
- On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total value of $346,806.39.
Adaptive Biotechnologies Price Performance
NASDAQ:ADPT opened at $26.71 on Thursday. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $30.74. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The company has a market capitalization of $4.26 billion, a P/E ratio of -65.15 and a beta of 2.18. The stock’s fifty day moving average is $26.37 and its two-hundred day moving average is $19.76.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.12. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $71.57 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%. The company’s quarterly revenue was down 10.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 EPS. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current year.
Institutional Trading of Adaptive Biotechnologies
A number of institutional investors and hedge funds have recently bought and sold shares of the business. University of Texas Texas AM Investment Management Co. purchased a new position in Adaptive Biotechnologies in the third quarter valued at $277,000. Ethic Inc. acquired a new stake in Adaptive Biotechnologies in the 3rd quarter valued at about $244,000. Pictet Asset Management Holding SA boosted its stake in shares of Adaptive Biotechnologies by 12.5% in the 3rd quarter. Pictet Asset Management Holding SA now owns 17,924 shares of the company’s stock valued at $518,000 after buying an additional 1,985 shares during the period. Parr Mcknight Wealth Management Group LLC acquired a new position in shares of Adaptive Biotechnologies during the third quarter worth about $217,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Adaptive Biotechnologies during the third quarter worth about $236,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the stock. National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Thursday, October 15th. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Finally, The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.06.
Read Our Latest Report on Adaptive Biotechnologies
Adaptive Biotechnologies News Summary
Here are the key news stories impacting Adaptive Biotechnologies this week:
- Positive Sentiment: Adaptive reported earnings of $0.02 per share, versus analysts’ expectation of a $0.10-per-share loss. Management also said the company achieved total-company profitability ahead of expectations. Third-quarter 2026 financial results
- Positive Sentiment: Revenue was $83.9 million, exceeding the $71.57 million analyst estimate. Core measurable residual disease (MRD) revenue grew 44%, a strong growth signal for a key business area. Q3 earnings and revenues top estimates
- Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 trading plan and retained 377,802 shares. The planned nature of the sale may make it less meaningful as a signal about near-term business prospects. Insider share sale
- Negative Sentiment: Revenue was still down 10.7% from the year-ago quarter, tempering the strong results versus analyst estimates. The company also reported a negative net margin. Quarterly earnings report
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.
Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
